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ABSTRACT The globally disseminated Streptococcus
pyogenes M1T1 clone causes a number of highly invasive
human diseases. The transition from local to systemic
infection occurs by an unknown mechanism; however
invasive M1T1 clinical isolates are known to express
significantly less cysteine protease SpeB than M1T1
isolates from local infections. Here, we show that in
comparison to the M1T1 strain 5448, the isogenic
mutant speB accumulated 75-fold more human plas-
min activity on the bacterial surface following incuba-
tion in human plasma. Human plasminogen was an
absolute requirement for M1T1 strain 5448 virulence
following subcutaneous (s.c.) infection of humanized
plasminogen transgenic mice. S. pyogenes M1T1 isolates
from the blood of infected humanized plasminogen
transgenic mice expressed reduced levels of SpeB in
comparison with the parental 5448 used as inoculum.
We propose that the human plasminogen system plays a
critical role in group A streptococcal M1T1 systemic
disease initiation. SpeB is required for S. pyogenes
M1T1 survival at the site of local infection, however,
SpeB also disrupts the interaction of S. pyogenes M1T1
with the human plasminogen activation system. Loss of
SpeB activity in a subpopulation of S. pyogenes M1T1 at
the site of infection results in accumulation of surface
plasmin activity thus triggering systemic spread.—Cole,
J. N., McArthur, J. D., McKay, F. C., Sanderson-Smith,
M. L., Cork, A. J., Ranson, M., Rohde, M., Itzek, A.,
Sun, H., Ginsburg, D., Kotb, M., Nizet, V., Chhatwal, G.
S., Walker, M. J. Trigger for group A streptococcal
M1T1 invasive disease. FASEB J. 20, E1139–E1145 (2006)
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Epidemic invasive group A Streptococcus (GAS, S. pyo-
genes) disease in the Western World since the mid-1980s
has been paralleled by the emergence of a globally
disseminated serotype M1T1 GAS clone (1). This M1T1
clone is associated with life-threatening infections such
as necrotizing fasciitis and streptococcal toxic shock
syndrome (2), while also causing uncomplicated infec-
tions in other patients (3). The mechanism that trig-
gers the transition from local to invasive infection by
GAS M1T1 is unknown, however, epidemiologic studies
have documented an inverse relationship between hu-
man invasive disease and the expression of the strepto-
coccal pyrogenic exotoxin B (SpeB) (4). SpeB is a
secreted cysteine protease initially expressed as a 40
kDa zymogen, which is then converted to its 28 kDa
active form by autocatalytic truncation (5). SpeB is
known to cleave host proteins including extracellular
matrix (ECM) components, cytokine precursors, im-
munoglobulins, and antimicrobial peptides (1, 6, 7)
and has been shown to play an important role in
establishing localized skin infections (8). SpeB also
degrades GAS virulence factors including the cell wall-
associated fibrinogen-binding antiphagocytic M1 pro-
tein (9, 10), various superantigens (11, 12), and the
secreted plasminogen activator streptokinase (13).
The capacity of GAS to assemble on its surface a
trimolecular complex containing streptokinase, fibrino-
gen, and plasminogen has been correlated with a propen-
sity for invasive infection (14). GAS is a highly specific
human pathogen and the streptokinase produced by this
organism displays a much greater affinity for human
plasminogen than mouse plasminogen (15). A major
advance in the understanding of GAS pathogenesis was
attained by Sun et al. (15) who established a humanized
plasminogen transgenic mouse model. These researchers
demonstrated that streptokinase and the activation of
plasminogen to plasmin is critical for GAS dissemination
in vivo, leading to the proposal that human plasminogen
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is hijacked for use as a virulence factor by GAS (15, 16). In
this study, we utilize the representative wild-type (WT)
clonal M1T1 strain 5448 and the precise, in-frame allelic
replacement mutant speB (11, 17) to investigate the
interplay between SpeB and human plasminogen co-
opted to the bacterial surface.
MATERIALS AND METHODS
Strains, media, and culture conditions
S. pyogenes strain 5448 (M1T1) and the isogenic speB mutant
have been described previously (12). All S. pyogenes strains
were routinely cultured at 37°C on horse-blood agar
(BioMe´rieux, Sydney, NSW, Australia) or in static liquid
cultures of Todd-Hewitt broth (Difco, Sydney, NSW, Austra-
lia) supplemented with 1% (w/v) yeast extract (THBY me-
dium). When required, SpeB was inactivated by growth in the
presence of cysteine protease inhibitor E64 (N-[N-(L-3-tran-
scarboxyirane-2-carbonyl)-L-Leucyl]-agmatine) (Sigma, Syd-
ney, NSW, Australia) at a final concentration of 28 M.
Hyaluronic acid capsule determination
Overnight cultures of S. pyogenes were diluted 1:10 in fresh
THBY media and grown to an optical density (OD) at 600 nm
(OD600) of 0.5–0.6. The hyaluronic acid capsule was ex-
tracted and quantified by the stains-all method (18).
Preparation of culture supernatant proteins
An overnight culture of S. pyogenes was diluted 1:10 in fresh
THBY medium and incubated at 37°C to late stationary phase
(approx. 16 h). The culture supernatant was harvested by
centrifugation at 8000 g for 20 min at 4°C and filter sterilized
through a 0.22 m filter (Millipore, Sydney, NSW, Australia)
for use in SpeB activity assays. For sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis,
equal volumes of cell-free supernatant and 10% (v/v) trichlo-
roacetic acid were mixed and incubated on ice for 1 h.
Following centrifugation at 15,000 g for 20 min at 4°C, the
pellet was washed with ice-cold 100% ethanol and centrifuged
at 15,000 g for 15 min at 4°C. The ethanol was removed by
aspiration, the pellet air-dried for 30 min and resuspended in
1 ml of 100 mM Tris-HCl (pH 7.6).
SpeB activity assays
Cysteine protease SpeB activity in S. pyogenes culture superna-
tants was determined according to the method of Hyto¨nen et
al. (19). To examine SpeB activity of large numbers of S.
pyogenes colonies, the Columbia skim milk plate-based assay
was used according to the method of Ashbaugh et al. (20).
Immunogold electron microscopy
S. pyogenes were fixed with 0.2% glutaraldehyde and 0.5%
formaldehyde for 1 h on ice, washed with cacodylate buffer
(0.1 M cacodylate, 0.9 M sucrose, 0.01 M MgCl2, 0.01 M
CaCl2; pH 6.9) containing 10 mM glycine and dehydrated
with ethanol following the progressive lowering of tempera-
ture protocol (10%, 30% ethanol on ice; 50% ethanol at
–20°C; 70%, 90%, 100% ethanol at –30°C; each step for 30
min). Samples were infiltrated with the Lowicryl® resin K4M
over 3 d before polymerization at –30°C with UV light (366
nm) for 2 d and 1 d at room temperature. Ultrathin sections
were collected with formvar-coated cover-slips and incubated
with SpeB specific IgG antibodies (75 g/ml, 10 h at 4°C),
washed with PBS and bound antibodies were made visible
with protein A/G coated gold-particles (10 or 15 nm in size).
Samples were counterstained with uranyl acetate for 1 min
and air-dried before examination in a Zeiss transmission
electron microscope EM910 at an acceleration voltage of
80 kV.
Plasminogen binding and cell surface plasmin activity
The binding of 125I-plasminogen was measured as reported
elsewhere (14). Approximately 70 ng of 125I-plasminogen was
added to 250 l of cell suspension and incubated at room
temperature for 45 min. The cells were harvested by centrif-
ugation, the supernatant carefully aspirated and pellet-associ-
ated radioactivity measured using an automatid Wallac
gamma counter (Perkin Elmer, Jugesheim, Germany). The
results were expressed as a percentage of input radioactivity.
All measurements were determined in triplicate.
Plasmin acquisition in human plasma by S. pyogenes isolates
was determined essentially as described previously (21). Fro-
zen plasma was purchased from the Red Cross Blood Bank
(Sydney, NSW, Australia), defrosted on ice and pooled.
Aliquots of pooled plasma were depleted of plasminogen by
incubation at 4°C on ice with excess lysine-sepharose® 4B for
1–2 h with gentle agitation. The extent of plasminogen
depletion and the plasmin activity of plasma was determined
by chromogenic assay with Spectrozyme® PL (American
Diagnostics Inc., Stamford, CT, USA), in the presence and
absence of streptokinase, and by Western blot using a poly-
clonal rabbit anti-human plasminogen antibody (Calbio-
chem, Kilsyth, VIC, Australia).
GAS were cultured overnight as stationary cultures in 25 ml
THY inoculated with 1 colony. GAS were pelleted by centrif-
ugation at 800 g, washed in 50 ml of PBS, pH 7.4, prewarmed
to 37°C, and resuspended to OD600  0.7 (corresponding to
log phase, in which streptokinase secretion is induced). A 2
ml aliquot of this suspension was pelleted as above and
resuspended in an equal vol of 100% plasma or plasminogen-
depleted plasma at 37°C. GAS were incubated in plasma for
3 h at 37°C, pelleted by centrifugation and washed twice with
1 vol of ice-cold 0.01 M EDTA, 0.1% (w/v) gelatin in PBS, pH
7.4. GAS were resuspended in 0.1% (w/v) gelatin in PBS, pH
7.4 to OD600 0.75. Aliquots (100 l) of this suspension were
incubated in triplicate in the presence and absence of 20 l
Spectrozyme® PL, 2.5 mM at 37°C for 60 min in a 96-well
plate. The reaction was quenched with 80 l of 1.75 M acetic
acid, the plates centrifuged at 800 g, and A405 of supernatants
determined.
Plasmin activity was determined as the difference between
A405 in the presence and absence of substrate, thus account-
ing for differences in the sedimentation efficiency of GAS
isolates. Each isolate was assayed in at least two independent
experiments. Plasmin equivalents and the linear range of the
assay (A4050–0.6) were determined using a standard curve
of purified plasmin (Roche Diagnostics, GmbH, Mannheim,
Germany).
Extraction of cell wall-associated proteins
Mutanolysin cell wall extracts were prepared from stationary
phase cultures of S. pyogenes as reported elsewhere (22).
Immunological reagents
Affinity-purified rabbit anti-SpeB IgG was purchased from
Toxin Technology Inc., Sarasota, FL, USA. Polyclonal rabbit
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antibodies were raised against purified recombinant S. pyo-
genes streptococcal enolase (SEN) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH). A rabbit polyclonal anti-
serum was raised against Lancefield group C streptokinase
(Sigma), which shares 90% identity with the streptokinase
(Ska) protein of S. pyogenes. All rabbit immunizations were
performed according to the method of Gillen et al. (23). The
production of mouse polyclonal antiserum against M1 pro-
tein is described elsewhere (24).
Western blot analysis
SDS-PAGE was performed according to the method of
Laemmli (25). Cell wall extracts or culture supernatant
proteins were transferred to nitrocellulose membrane at 100
V for 1 h using the Mini Trans-Blot® (Bio-Rad) (26). The
membranes were blocked in a solution of 5% (w/v) skim milk
(Difco) in PBS (137 mM NaCl, 2.7 mM KCl, 7.9 mM
Na2HPO4, 1.5 mM KH2PO4; pH 7.4) for 1 h at room
temperature. After a 10 min wash with PBS, the membranes
were incubated for 2 h with primary Ab diluted 1:1,000 in
PBS. Following three washes for 10 min each with PBS, the
membranes were incubated for 1 h with a 1:1,000 dilution of
goat anti-rabbit IgG HRP conjugate (Bio-Rad) for SpeB, Ska,
SEN, and GAPDH blots, or a 1:1,000 dilution of goat anti-
mouse IgG HRP conjugate (Bio-Rad) for M1 protein blots.
Excess secondary Ab was removed by three PBS washes for 10
min each and all blots developed in a solution of 100 mM
Tris-HCl (pH 7.6) containing 1.4 mM diaminobenzidine and
0.06% (v/v) hydrogen peroxide.
Protease assays
SpeB protease (5 g; Toxin Technology Inc.) was mixed with
5 g of purified human plasminogen or fibrinogen (14),
adjusted to final vol of 25 l with PBS (pH 7.4) and incubated
at 37°C for 3 h. Cleavage of substrate protein was determined
by SDS-PAGE analysis. Positive controls containing 5 g SpeB
and 25 g -casein (Sigma) were used in all assays. Negative
controls containing protease or substrate only were also
included.
Streptococcal infection model
AlbPLG1 transgenic mice (Tg) (27) heterozygous for the
human plasminogen transgene were backcrossed greater
than n  6 with C57BL/J6 mice (Animal Resources Centre,
Perth, Australia). Nontransgenic (Tg) littermates were used
as controls in all experiments. Streptococcal strains used for
inocula were harvested at midlog phase (OD600 approx. 0.5).
Bacteria were washed with an equal vol of sterile 0.7% saline
and diluted to the required inoculum. The number of viable
bacteria present was determined by counting colony-forming
units (CFU) after plating a dilution series onto blood agar
plates (BioMe´rieux). Groups of 10 Tg mice and Tg litter-
mates were infected with either 2.8  108 CFU (5448) or
1.35  108 CFU (speB mutant) via a s.c. injection into a
shaved region of the right flank of each mouse. Mortality was
recorded over 14 d.
For experiments examining the dissemination of strepto-
cocci during infection, a separate cohort of Tg mice was
inoculated s.c. Wild-type 5448 was inoculated using 1.58 
109 CFU (n4; 1 mouse succumbed to infection on day 2)
and 1.49  108 CFU (n1). The 5448 mutant speB was
inoculated using 1.71  109 CFU (mutant; n4; 1 mouse
succumbed to infection on day 2) and 4.5  107 CFU (n1).
On day 3 postinfection, mice were sacrificed by CO2 asphyx-
iation, and representative bacteria were isolated from the site
of initial infection and bacterial loads present in the blood-
stream were determined by plating serial dilutions onto blood
agar. All experiments were conducted according to the
Guidelines for the Care and Use of Laboratory Animals
(National Health and Medical Research Council, Australia)
and were approved by the University of Wollongong Animal
Ethics Committee.
Statistical analyses
Average capsular hyaluronic acid, SpeB activity and plasmin-
ogen binding for 5448 and speB were compared using the
two-tailed unpaired t test. Cell surface plasmin activity levels
were evaluated using the Welch ANOVA (assuming unequal
variances). Differences in survival of Tg and Tg mice
infected with 5448 and speB were determined by the log-
Figure 1. In vitro characterization of M1T1 S. pyogenes strain
5448 (WT) and the isogenic speB mutant. a) 5448 and the
speB mutant express equivalent amounts of capsular hyal-
uronic acid (mean	sd). b) Secreted SpeB protease activity
(mean	sd) is abolished in the speB mutant compared with
5448. c) Electron microscopic analyses detected SpeB zymo-
gen at the ExPortal microdomain of 5448, but not speB (data
not shown). d) Equivalent amounts of purified human 125I-
labeled plasminogen (mean	sd) are bound by 5448 and
speB. e) The speB mutant cell surface accrues a 75-fold
higher concentration of human plasma activity (mean	sd)
compared with strain 5448.
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rank test. Mean bacterial loads in the bloodstream (log10
CFU) of Tg mice infected with 5448 or speB were compared
using the two-tailed unpaired t test. The t and log-rank tests
were performed using GraphPad Prism version 4.02 (Graph-
Pad Software Inc., San Diego, CA, USA). The Welch ANOVA
was performed using JMP (SAS Institute, NC, USA).
RESULTS
Characterization of M1T1 strains 5448 and speB
Both WT and isogenic speB mutant strains expressed
identical amounts of hyaluronic acid capsule (Fig. 1a),
excluding a pleiotropic mutation that confounded ear-
lier studies of SpeB in GAS pathogenesis (20). Secreted
cysteine protease activity was undetectable in the speB
mutant (P0.05; Fig. 1b), and SpeB zymogen was
detected only at the cell wall ExPortal microdomain
(28) of the parent M1T1 strain (Fig. 1c). Nonetheless,
both WT and speB mutant bound equivalent amounts
of purified human plasminogen (Fig. 1d). These data
indicate that, like the GAS M5 strain characterized by
Rosch and Caparon (28), the M1T1 clone also secretes
SpeB zymogen via the ExPortal microdomain. The
presence or absence of SpeB does not affect the
capacity of M1T1 GAS to bind purified human plasmin-
ogen, suggesting that the surface plasminogen recep-
tors 
-enolase (SEN) (29) and GAPDH (30) are not
disabled by SpeB proteolysis. However, in comparison
to the WT strain, the isogenic speB mutant accumu-
lated 75-fold higher levels of human plasmin activity on
the bacterial surface following incubation in human
plasma for 3 h at 37°C (P0.05; Fig. 1e).
Analysis of plasminogen activation system
components
To elucidate the underlying reason(s) for the en-
hanced capacity of the cysteine protease-deficient GAS
strain to accumulate surface plasmin activity, we com-
pared WT and speB mutant strains for the expression
of cell wall-associated plasminogen and fibrinogen re-
ceptors and for secretion of streptokinase. Active 28
kDa SpeB was identified only in supernatants of the WT
strain; with addition of the SpeB inhibitor E64 just the
40 kDa SpeB zymogen form was detected (Fig. 2a).
Streptokinase was present only in supernatants of the
speB mutant or the WT parent strain grown in the
presence of E64 (Fig. 2a). The fibrinogen-binding M1
protein was found in cell wall extracts only in the
absence of SpeB activity, whereas plasminogen recep-
tors SEN and GAPDH were detected in cell wall extracts
of both WT and speB mutant (Fig. 2a). SpeB was also
observed to degrade plasminogen directly, as well as
fibrinogen, which forms a trimolecular complex with
streptokinase and plasminogen bound to the GAS
surface (14, 31) (Fig. 2b). Thus, SpeB interferes with
the accumulation of GAS surface bound plasmin activ-
ity by cleaving four critical factors: plasminogen, the
plasminogen activator streptokinase, fibrinogen and
the fibrinogen-binding M1 protein (16).
Infection of humanized plasminogen transgenic mice
We next took advantage of heterozygous AlbPLG1 mice
that express a human plasminogen transgene (Tg)
(15) and littermate C57BL/J6 control mice (Tg) to
examine the virulence of WT M1T1 GAS and the
Figure 2. Western blot analysis and in vitro SpeB protease assays. a)
Blots of secreted (SpeB and Ska) or cell wall-associated proteins (M1,
SEN, and GAPDH) harvested in the presence or absence of SpeB
inhibitor E64 for 5448 (WT) and the isogenic speB mutant. Lane 1,
5448 culture supernatant or cell wall (–E64); lane 2, speB culture
supernatant or cell wall (–E64); lane 3, 5448 culture supernatant or
cell wall (E64); lane 4, speB culture supernatant or cell wall
(E64). Filled arrowheads indicate major immunoreactive bands. b)
SpeB protease degrades human plasminogen and fibrinogen, which
play a key role in the accumulation of surface-bound plasmin activity
by S. pyogenes. Lane 1, SpeB; lane 2, -casein; lane 3, SpeB and
-casein (positive control); lane 4, plasminogen; lane 5, SpeB and
plasminogen; lane 6, fibrinogen; lane 7, SpeB and fibrinogen. Molecular mass markers are given in kilo-Daltons (kDa).
E1142 Vol. 20 August 2006 COLE ET AL.The FASEB Journal
isogenic speB mutant in a s.c. infection model. Only
through use of this transgenic mouse line can one
investigate the interaction of GAS with the plasmino-
gen activation system, since this interaction is highly
specific for human plasminogen (15, 16). In compari-
son to infection of nontransgenic control mice, the
virulence of WT M1T1 strain was significantly increased
in Tg mice (P0.05; 10% vs. 80% mortality) (Fig. 3a).
This result indicates that the human plasminogen
system plays a crucial role in the ability of M1T1 GAS to
initiate a lethal systemic infection. In comparison to the
WT GAS parent strain, the isogenic speB mutant was
attenuated for virulence in the Tg plasminogen-hu-
manized mice (P0.05; 80% vs. 20% mortality) (Fig.
3a, b). Additionally, in comparison to GAS strain 5448,
72 h postinfection of Tg mice the isogenic speB
mutant displayed significantly fewer bacterial counts in
the blood (P0.05; Fig. 3c). These data support a role
for SpeB in GAS survival at the site of local infection in
the skin, as proposed by Svensson et al. (8), and
suggested this difference may translate into an overall
decreased lethality on challenge with the speB mutant.
To further examine the interaction between the
human plasminogen system and GAS cysteine protease
SpeB, we examined the SpeB expression status of WT
GAS isolated from the blood of the infected plasmino-
gen-humanized Tg mice. The WT GAS used in the
initial challenge uniformly expressed high levels of
cysteine protease activity (100% of inoculum colonies
tested; n100). Bacteria isolated from the s.c. site of
infection expressed a mixed phenotype (74%, 66%,
63%, and 31% of lesion recovered colonies SpeB-
negative from 4 s.c. inoculated Tg mice). Bacteria
recovered from the blood unvaryingly demonstrated
Figure 3. Survival curves, bacterial counts, and SpeB expres-
sion phenotype following s.c. infection of humanized plas-
minogen transgenic mice (Tg) and nontransgenic control
mice (Tg) with S. pyogenes strain 5448 (WT) or the isogenic
speB mutant. a) The virulence of 5448 is increased in
transgenic mice compared with the nontransgenic control. b)
The virulence of the speB mutant was attenuated in both
transgenic and control mice. c) Bacterial counts in the
bloodstream of Tg mice 72 h postinfection are significantly
higher for 5448 compared with speB. d) Compared with the
SpeB activity of 5448 colonies isolated from the inoculum, the
5448 Tg lesion isolates exhibit a varied SpeB-expression
phenotype, while the 5448 Tg blood isolates have signifi-
cantly reduced SpeB activity.
 
Figure 4. Proposed model for group A streptococcal systemic
disease initiation. a) S. pyogenes M1T1 (blue) gain entry
through the skin and a host innate immune response is
initiated. b) During the initial stages of infection, S. pyogenes
M1T1 express SpeB to combat the host response. c) Loss of
SpeB activity in a subpopulation of group A streptococci
(green) leads to the accumulation of surface plasmin activity.
d) Transition of S. pyogenes M1T1 is facilitated by surface
plasmin activity, resulting in systemic infection.
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very low SpeB activity (100% of blood isolated colonies
examined SpeB-negative) (Fig. 3d). This finding is
consistent with the epidemiologic observation that
M1T1 clinical isolates from human invasive disease
express reduced levels of SpeB (4).
DISCUSSION
The mechanism utilized by GAS to switch from local-
ized to systemic infection is presently unknown. How-
ever, subversion of the host plasminogen activation
system is thought to play a key role (15, 16). In this
study, we have shown that the absence of cysteine
protease SpeB activity is required for the accumulation
of plasmin activity on the cell surface of M1T1 GAS. In
a humanized plasminogen transgenic mouse model,
the loss of SpeB activity at the site of infection triggers
the systemic dissemination of M1T1 GAS in vivo. These
data support the proposal that human plasminogen
plays a critical role in the initiation of GAS invasive
disease.
Plasminogen is the proenzyme form of plasmin, a
blood clot-dissolving serine protease, which degrades
ECM components and activates matrix metallopro-
teases (32). In S. pyogenes, two distinct pathways have
been identified for the binding of plasminogen to the
cell surface. The direct pathway is mediated by the
plasminogen-binding GAS M-like protein (PAM) (33),
streptococcal enolase (SEN) (29), and GAPDH (29,
34). Indirect plasminogen-binding requires the forma-
tion of a trimolecular complex between plasminogen,
streptokinase, and fibrinogen, which is bound to the
GAS cell surface via plasminogen or fibrinogen recep-
tors (14, 31, 35). Human plasminogen is converted to
plasmin by the plasminogen activators urokinase (uPA)
and tissue-type plasminogen activator (tPA), or by
secreted microbial activators including the GAS viru-
lence factor streptokinase (36). Here, we demonstrate
that the presence of SpeB does not interfere with the
binding of plasminogen to the GAS cell surface. How-
ever, SpeB degrades four key factors required for the
accumulation of surface plasmin activity on the GAS
surface: plasminogen, streptokinase, fibrinogen, and
the fibrinogen-binding M1 protein.
Utilizing a speB-negative mutant and a humanized in
vivo model for impetigo in which neonatal foreskin was
engrafted onto the hind flanks of CB-17 scid mice,
Svensson et al. (8) determined that SpeB protease plays
a critical role in the establishment of host tissue tropism
by GAS. Our accumulated data suggest that SpeB, while
contributing to localized infection, simultaneously mit-
igates the potential interaction of M1T1 GAS with the
human plasminogen activation system. The ablation of
SpeB expression in WT M1T1 GAS in the blood of
plasminogen-humanized Tg mice indicates that the
loss of SpeB activity in a subpopulation of bacteria
occurs at the site of infection, allowing accumulation of
surface plasmin activity. This subpopulation thus gain
enhanced invasive propensity, favoring transition of
GAS from the site of infection to the blood. In our
model, vascular leakage induced by M protein complex-
ing with fibrinogen to activate heparin binding protein
release from neutrophils, may provide a source of
plasminogen at the site of infection (37) (Fig. 4). The
subpopulation of GAS undergoing a phase shift to
eliminate SpeB expression gain not only the capacity to
accumulate cell surface plasmin activity and spread
systemically, but also elaborate greater levels of su-
perantigens (12), the causative agents of streptococcal
toxic shock.
The expression of the streptococcal cysteine protease
SpeB and the human invasive disease severity are
inversely related in M1T1 clonal isolates (4). The
model we propose for GAS human systemic disease
initiation accounts for this previously perplexing clini-
cal observation and describes a mechanism by which
systemic disease initiation occurs. The elucidation of
the mechanism by which GAS causes human invasive
disease will inform future treatment and prevention
strategies.
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SPECIFIC AIMS
The globally disseminated M1T1 clone of Streptococcus
pyogenes (group A Streptococcus; GAS) causes a number
of highly invasive human diseases, including necrotiz-
ing fasciitis and streptococcal toxic shock-like syn-
drome. Although the transition from local to systemic
infection occurs by an unknown mechanism, invasive
M1T1 clinical isolates express significantly less cysteine
protease SpeB than M1T1 isolates from localized infec-
tions. Subversion of the host plasminogen activation
system by GAS may also play a key role in systemic
disease initiation. In this study, we utilize the represen-
tative wild-type (WT) clonal M1T1 isolate 5448 and the
isogenic mutant speB to investigate the interaction
between SpeB and human plasminogen in GAS invasive
disease. The specific aims were: 1) to characterize capsule
expression, SpeB protease activity, plasminogen-binding
capacity, and accumulation of surface-bound plasmin
activity in WT and speB strains; 2) to examine the
virulence of WT and speB strains in a humanized plas-
minogen transgenic mouse model of subcutaneous (s.c.)
infection; and 3) to analyze the SpeB activity of WT
colonies isolated from the skin lesions and blood of
infected plasminogen-humanized mice.
PRINCIPAL FINDINGS
1. Characterization of M1T1 5448 and speB
The WT and speB mutant expressed identical
amounts of hyaluronic acid capsule (Fig. 1a), exclud-
ing a pleiotropic mutation that confounded earlier
studies of SpeB in GAS pathogenesis. SpeB protease
activity was undetectable in the speB mutant
(P0.05; Fig. 1b), and SpeB zymogen was identified
only at the ExPortal microdomain of the WT strain
(Fig. 1c). Nonetheless, equivalent amounts of human
plasminogen were bound by the WT and speB
mutant (Fig. 1d), suggesting that SpeB does not
affect the capacity of M1T1 GAS to bind human
plasminogen. Compared with the WT strain, speB
accumulated 75-fold higher levels of plasmin activity
on the bacterial surface following incubation in
human plasma (P0.05; Fig. 1e). These data suggest
that SpeB may interfere with the accumulation of
plasmin on the GAS cell surface.
2. Infection of humanized plasminogen
transgenic mice
Compared with nontransgenic control mice (Tg),
the virulence of the WT strain was significantly
enhanced in humanized plasminogen transgenic
mice (Tg) (P0.05; 10% vs. 80% mortality) (Fig.
2a), indicating that human plasminogen is essential
for M1T1 virulence. In comparison to the WT GAS
parent strain, the speB mutant was attenuated for
virulence in the Tg mice (P0.05; 80% vs. 20%
mortality) (Fig. 2a, b) and displayed significantly
fewer bacterial counts in the blood (P0.05; Fig. 2c).
These data support a role for SpeB in GAS survival at the
site of local skin infection.
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3. SpeB activity of 5448 in vivo isolates
The WT strain used in the initial challenge uniformly
expressed high levels of SpeB protease activity (100% of
inoculum colonies was SpeB-positive; n100). WT bac-
teria recovered from the lesions of four Tg mice
expressed a mixed SpeB phenotype (74%, 66%, 63%
and 31% of lesion colonies examined were SpeB-
negative). However, WT bacteria recovered from the
blood unvaryingly demonstrated very low SpeB activity
(100% of blood colonies examined were SpeB-nega-
tive) (Fig. 2d). This finding is consistent with the
epidemiologic observation that M1T1 clinical isolates
Figure 1. In vitro characterization of M1T1 S. pyogenes strain
5448 (WT) and the isogenic speB mutant. a) 5448 and the
speB mutant express equivalent amounts of capsular hyal-
uronic acid (meansd). b) Secreted SpeB protease activity
(meansd) is abolished in the speB mutant compared
with 5448. c) Electron microscopic analyses detected SpeB
zymogen at the ExPortal microdomain of 5448, but not
speB (data not shown). d) Equivalent amounts of purified
human 125I-labeled plasminogen (meansd) are bound by
5448 and speB. e) The speB mutant cell surface accrues a
75-fold higher concentration of human plasma activity
(meansd) compared with strain 5448.
Figure 2. Survival curves, bacterial counts and SpeB expres-
sion phenotype following s.c. infection of humanized plas-
minogen transgenic mice (Tg) and nontransgenic control
mice (Tg) with S. pyogenes strain 5448 (WT) or the isogenic
speB mutant. a) The virulence of 5448 is increased in
transgenic mice compared with the nontransgenic control. b)
The virulence of the speB mutant was attenuated in both
transgenic and control mice. c) Bacterial counts in the
bloodstream of Tg mice 72 h postinfection are significantly
higher for 5448 compared with speB. d) Compared with the
SpeB activity of 5448 colonies isolated from the inoculum, the
5448 Tg lesion isolates exhibit a varied SpeB-expression
phenotype, while the 5448 Tg blood isolates have signifi-
cantly reduced SpeB activity.
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from human invasive disease express reduced levels of
SpeB.
CONCLUSIONS AND SIGNIFICANCE
The mechanism utilized by GAS to switch from local-
ized to systemic infection is presently unknown. In this
study, we have shown that the absence of cysteine
protease SpeB activity is required for the accumulation
of plasmin activity on the cell surface of M1T1 GAS. In
a humanized plasminogen transgenic mouse model of
s.c. infection, the loss of SpeB activity at the site of
infection triggers the systemic dissemination of M1T1
GAS in vivo. These data support the proposal that
human plasminogen plays a critical role in the initia-
tion of GAS invasive disease.
Our accumulated data suggest that SpeB, while con-
tributing to localized infection, simultaneously miti-
gates the potential interaction of M1T1 GAS with the
human plasminogen activation system. The ablation of
SpeB expression in WT M1T1 GAS in the blood of
plasminogen-humanized Tg mice indicates that the
loss of SpeB activity in a subpopulation of bacteria
occurs at the site of infection, allowing accumulation of
surface plasmin activity. This subpopulation thus gain
enhanced invasive propensity, favoring transition of
GAS from the site of infection to the blood. In our
model, vascular leakage induced by M protein complex-
ing with fibrinogen to activate heparin binding protein
release from neutrophils, may provide a source of
plasminogen at the site of infection (Fig. 3).
The expression of the streptococcal cysteine protease
SpeB and human invasive disease severity are inversely
related in M1T1 clonal isolates. The model we propose
accounts for this previously perplexing clinical observa-
tion and describes a mechanism by which systemic
disease initiation occurs. The elucidation of the mech-
anism by which GAS causes human invasive disease will
inform future treatment and prevention strategies.
 
Figure 3. Proposed model for group A streptococcal systemic
disease initiation. a) S. pyogenes M1T1 (blue) gain entry
through the skin and a host innate immune response is
initiated. b) During the initial stages of infection, S. pyogenes
M1T1 express SpeB to combat the host response. c) Loss of
SpeB activity in a subpopulation of group A streptococci
(green) leads to the accumulation of surface plasmin activity.
d) Transition of S. pyogenes M1T1 is facilitated by surface
plasmin activity, resulting in systemic infection.
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